

07
UPDATE

New Zealand
Pharmaceutical Schedule

Effective 1 October 2007

Cumulative for September and October 2007

Section H cumulative for August, September and October 2007

Investing in Health

PHARMAC
Pharmaceutical Management Agency

Contents

Summary of PHARMAC decisions – effective 1 October 2007	3
Looking hard at a tender issue	6
PHARMAC model highlighted in Canadian study	7
Update on metoprolol succinate (Betaloc CR) and felodipine (Plendil ER)	8
Sensory products – removal of some prescribing restrictions	9
Section H mailing list.....	9
Simvastatin – alternative brand listed.....	9
New osmotic laxative subsidised	10
Colifoam – clarification of dose.....	10
Etanercept – named specialists update	10
Tender News.....	11
Looking Forward	11
Sole Subsidised Supply products cumulative to October 2007	12
New Listings.....	20
Changes to Restrictions.....	22
Changes to Subsidy and Manufacturer’s Price.....	27
Changes to Section G: Safety Cap Medicines.....	29
Changes to Sole Subsidised Supply	29
Delisted Items	30
Items to be Delisted	32
Section H changes to Part II	34
Index.....	38

Summary of PHARMAC decisions

EFFECTIVE 1 OCTOBER 2007

New listing (pages 20 – 21)

- Mesalazine (Pentasa) suppos 1 g
- Omeprazole (Dr Reddy's Omeprazole) cap 10 mg, 20 mg and 40 mg
- Lactulose (Duphalac) oral liq 10 g per 15 ml, 1,000 ml – only on a prescription
- Macrogol 3350 (Movicol) powder 13.125 g, sachets – not more than 60 sachets per prescription – Special Authority – Retail pharmacy
- Simvastatin (SimvaRex) tab 10 mg, 20 mg and 40 mg
- Ibuprofen (Brufen) tab 600 mg, 30 tablet pack
- Citalopram hydrobromide (Citalopram – Rex) tab 20 mg
- Midazolam (Pfizer) inj 1 mg per ml, 5 ml and inj 5 mg per ml, 3 ml
- Budesonide with eformoterol (Symbicort Rapihaler) aerosol inhaler 100 µg with eformoterol fumarate 6 µg, 120 dose OP and aerosol inhaler 200 µg with eformoterol fumarate 6 µg, 120 dose OP – Special Authority – Retail pharmacy
- Ipratropium bromide (Apo-Ipravent) aqueous nasal spray, 0.03%, 30 ml OP
- Soy infant formula (S26 Soy) powder – Special Authority – Retail Pharmacy

Changes to restriction (pages 22 – 26)

- Hydrocortisone acetate (Colifoam) rectal foam 10%, CFC-free (14 applications) – change to description
- Metoprolol succinate (Betaloc CR) tab long-acting 23.75 mg, 47.5 mg, 95 mg, and 190 mg – addition of higher subsidy by endorsement
- Phenoxymethylpenicillin (Penicillin V) – grans for oral liq benzathine 125 mg per 5 ml and 250 mg per 5 ml – change to description
- Quetiapine (Seroquel) tab 25 mg, 100 mg, 200 mg, and 300 mg – removal of endorsement criteria
- Mycophenolate mofetil – amended Special Authority criteria
- Aciclovir (Zovirax) eye ointment 3% – removal of Retail pharmacy – specialist
- Ciprofloxacin (Ciloxan) eye drops 0.3% - removal of Retail pharmacy – specialist
- Dexamethasone with framycetin and gramicidin (Sofradex) ear/eye drops 500 µg with framycetin sulphate 5 mg and gramicidin 50 µg per ml - removal of Retail pharmacy – specialist when used in the treatment of eye conditions.
- Gentamicin sulphate (Gentoptic) eye drops 0.3% - removal of Retail pharmacy - Specialist

Summary of PHARMAC decisions – effective 1 October 2007 (continued)

- Betaxolol hydrochloride eye drops 0.25% (Betoptic S) and eye drops 0.5 % (Betoptic) - removal of Retail pharmacy - Specialist
- Dexamethasone (Maxidex) eye oint 0.1% and eye drops 0.1% - removal of Retail pharmacy - Specialist
- Dexamethasone with neomycin and polymixin B sulphate (Maxitrol) eye oint and eye drops - removal of Retail pharmacy - Specialist
- Diclofenac sodium (Voltaren Ophtha) eye drops 1 mg per ml - removal of Retail pharmacy – specialist
- Fluorometholone (Flucon) eye drops 0.1% - removal of Retail pharmacy – specialist
- Levobunolol (Betagan) eye drops 0.25% and 0.5% - removal of Retail pharmacy – specialist
- Prednisolone acetate eye drops 0.12% (Pred Mild) and eye drops 1% (Pred Forte) - removal of Retail pharmacy – specialist
- Tobramycin (Tobrex) eye oint 0.3% and eye drops 0.3% - removal of Retail pharmacy – specialist
- Brimonidine tartrate (AFT) eye drops 0.2% - removal of Retail pharmacy – specialist
- Dorzolamide hydrochloride (Trusopt) eye drops 2% - removal of Retail pharmacy – specialist
- Dorzolamide hydrochloride with timolol maleate (Cospot) eye drops 2% with timolol maleate 0.5% - removal of Retail pharmacy – specialist
- Timolol maleate (Apo-Timop, Timoptol XE) eye drops 0.25% and 0.5% - removal of Retail pharmacy – specialist
- Brimonidine tartrate with timolol maleate (Combigan) eye drops 0.2% with timolol maleate 0.5% - removal of Retail pharmacy – specialist
- Pilocarpine (Minims) eye drops 2% single dose – amended Special Authority criteria
- Fat supplement (Calogen, Liquigen, MCT oil) – amended Special Authority criteria
- Paediatric products (Nutrini Energy RTH, Nutrini RTH, Fortini, Pediasure, Resource Just for Kids, Fortini Multifibre) – amended Special Authority criteria

Increased subsidy (pages 27 – 29)

- Colestipol hydrochloride (Colestid) sachets 5 g
 - Captopril (Apo-Captopril) tab 12.5 mg, 25 mg and 50 mg
 - Digoxin oral liq 50 µg per ml, tab 250 µg (Lanoxin) and tab 62.5 µg (Lanoxin PG)
-

Summary of PHARMAC decisions – effective 1 October 2007 (continued)

- Metoprolol succinate (Betaloc CR) tab long-acting 23.75 mg, 47.5 mg, 95 mg and 190 mg – higher subsidy with endorsement
- Metoprolol tartrate (Lopresor) tab 50 mg
- Oxybutynin (Apo-Oxybutynin) oral liq 5 mg per 5 ml
- Thyroxine (Eltroxin) tab 50 μ g and 100 μ g
- Phenoxymethylpenicillin (Penicillin V) (AFT) grans for oral liq 125 mg per 5 ml and 250 per 5 ml
- Colistin sulphomethate (Colistin-Link) inj 150 mg
- Fusidic acid (Fusidin) tab 250 mg

Decreased subsidy (pages 27 – 29)

- Mesalazine (Asacol) tab 400 mg and suppos 500 mg
- Dextrose with electrolytes soln with electrolytes, 500 ml OP (Plasma-Lyte Oral) and 946 ml OP (Pedialyte – Fruit)
- Povidone iodine (Betadine) antiseptic soln 10%
- Quetiapine (Seroquel) tab 25 mg, 100 mg, 200 mg and 300 mg
- Paclitaxel inj 30 mg, 100 mg (Taxol) and 1 mg for ECP (Baxter)
- Interferon beta-1-beta (Betaferon) inj 8 million iu per 1 ml

Looking hard at a tender issue

Tendering for off-patent medicines has been a successful strategy that has served us well over the years. Like all good ideas there is always room for improvement and the 2007/08 tender consultation includes a proposed change that could provide greater access to alternate brands of medicines for patients.

Tendering is a fairly commonly used commercial strategy that is widely used in both the public and private sectors.

PHARMAC ran its first tender in 1997, for one product – paracetamol. Back then the idea that pharmaceutical companies could compete for a single market was fairly revolutionary. Now each year the tender includes over 500 line items and the use of generics has become commonplace. In some cases, price reductions of up to 90% have been achieved through the tender.

The PHARMAC tender has produced savings in excess of \$300 million, and now sources more than 40% of all subsidised medicines (by prescription number).

In a small market like New Zealand, the tender has also been an important mechanism for securing supply of small-volume but important medicines through a contract. That won't be changing.

What could be changing is the application of "sole supply". Traditionally, the tender has granted virtually the entire New Zealand market to one brand of a pharmaceutical for a period of up to three years. This provided maximum incentive to the pharmaceutical companies to offer the best price. Across the

New Zealand population, this has created enormous efficiencies and released funding that then became available to purchase newer medicines or other health services. For the vast majority of people, changing brands of medicines creates no difficulties.

In some cases, however, small numbers of people experience genuine clinical difficulties in changing brands, perhaps in response to slight differences in the amount of active ingredient, or differences in the excipients.

Under sole supply, there is not a great deal of flexibility to provide people with access to brands other than the one that wins the tender. This has been highlighted in recent times around the brand change for methylphenidate.

Consultation on the 2007 tender round has created the opportunity to introduce an evolution of this policy to allow some flexibility for patients and doctors, while



continuing to offer tender winners the major part of the market.

Under the proposed change, up to around 1% of patients would have access to an alternative brand of a particular pharmaceutical provided they can demonstrate clinical need.

The proposed changes would require doctors to provide information on clinical responses to brand changes before allowing access to a brand other than the one that had been awarded the tender contract.

Applications for individual patients would be assessed by a panel of practicing doctors, and access to alternative brands would be granted on clinical grounds (inadequate or adverse response) through a Special Authority

mechanism similar to that used for many other medicines.

In looking at this change, we have to be careful not to lose the considerable benefits that tendering produces.

We are already careful to assess whether it is appropriate to include a medicine in the tender, and have removed some items from the tender in the past because clinical risks have been identified. The proposed changes represent evolution rather than revolution, and we will be taking feedback into account before deciding whether to implement any changes.

**The consultation letter is available on the PHARMAC website www.pharmac.govt.nz. Feedback is being sought until 26 October 2007.*

PHARMAC model highlighted in Canadian study

Canadian researchers have cited New Zealand as an example of how negotiations with pharmaceutical companies can produce major savings on prescription medicines.

Canadian health funders are struggling with a fast-growing pharmaceutical bill amid debate over a way forward.

A paper by University of British Columbia researcher Dr Steve Morgan, published in *Healthcare Policy* journal, suggests using a New Zealand-style approach would help address the problems being faced in Canada.

It examined price differences across four major classes of medicines and concluded:

“The results suggest that potential price savings for Canada in these drug classes are in the order of 21% to 79%. Such price differences would translate into billions of

dollars in annual savings if applied across Canada.”

On average, the study showed Canadian prices are 51% per cent higher than New Zealand’s in four categories of common medicines -- for cholesterol control, high blood pressure, depression and ulcers or acid reflux.

“Canada can, and should, expect manufacturers of tried-and-true medicines to price them competitively,” Dr Morgan told the Vancouver Sun.

“By overpaying for these drugs, we send firms the wrong signal -- that we’ll reward imitation as if it was innovation. The New Zealand experience . . . shows that tough but fair negotiation is more powerful than regulation.”

Update on metoprolol succinate (Betaloc CR) and felodipine (Plendil ER)


Over recent months we have provided you with information about likely funding changes for Betaloc CR and Plendil ER 2.5 mg. AstraZeneca has now formally increased its prices for all strengths of Betaloc CR although it has chosen not to increase the price for Plendil ER 2.5 mg.

The changes from 1 October 2007 are as follows:

- All patients taking metoprolol succinate long-acting tablets (Betaloc CR) prior to 1 October 2007 are eligible for a full subsidy with prescriber endorsement;
- All new post myocardial infarction (MI) patients are eligible for a full subsidy of Betaloc CR with prescriber endorsement;
- All other new patients (i.e., excluding post MI) will have to pay a manufacturer's surcharge for Betaloc CR or use an alternative fully subsidised product.
- Repeat dispensings for Betaloc CR will be fully subsidised without the need for endorsement where the initial dispensing was before 1 October 2007.

See page 22 for full details.

PHARMAC will review the subsidy arrangements over the coming months as information about the likelihood of a generic competitor becomes available. PHARMAC has an agreement to fund a generic, once it is registered by Medsafe. The generic metoprolol succinate would cost 53% less than Betaloc CR.



Due to the significantly increased expenditure on Betaloc CR, PHARMAC will be reviewing its ability to fund other new pharmaceutical proposals. This may mean that some current proposals awaiting funding may be delayed or not progressed.

We appreciate that the endorsement will be inconvenient for both clinicians and pharmacists, and that fully funded metoprolol succinate will not be available for all new patients (except new post-MI patients); however this interim solution will prevent the need for any patient currently stabilised on Betaloc CR to be switched to an alternative product or pay a manufacturer's surcharge.

BPAC^{NZ} has developed information on alternatives to Betaloc CR for NEW patients. This information will be distributed to all clinicians and pharmacists and is also available on the BPAC^{NZ} and PHARMAC websites (www.bpac.org.nz and www.pharmac.govt.nz).

We will continue to keep you informed about any further changes in this area as information becomes available.

Sensory products – removal of some prescribing restrictions

A number of prescriber restrictions will be removed from medicines listed in the Sensory Therapeutic Group of the Pharmaceutical Schedule from 1 October 2007. This will allow prescribers such as nurse prescribers and optometrists, within their scope of practice, to access subsidies for their patients.

The removal of specialist restrictions is not related to any changes to the safety profiles of these medicines and it will remain the responsibility of the prescriber to ensure these treatments are prescribed safely.

An issue raised through consultation was the clinical risks associated with the use of some of these medicines. One group stressed the importance of education to prevent adverse drug events. To that end, we will be working with BPAC^{NZ} to disseminate prescriber information regarding the safe use of ocular steroids and other treatments in this therapeutic group.

Section H mailing list

We are reviewing the mailing list for Section H of the Pharmaceutical Schedule (for hospital drugs). Currently all our subscribers to the Schedule mailing list receive a copy of the Section H book. We understand that many Schedule users do not require a copy of Section H as it is aimed for use mainly by hospital pharmacies and hospital procurement.

The next published Section H book will be distributed late in November 2007 and will only be mailed to hospital pharmacies, hospital procurement and paying subscribers. For other subscribers, if you would like to continue receiving copies of the Section H book, please let us know by email to schedule@pharmac.govt.nz.

Simvastatin – alternative brand listed

A further brand of simvastatin tablets will be listed from 1 October 2007. Rex Medical Ltd's brand of simvastatin 10 mg, 20 mg and 40 mg tablets (SimvaRex) will be fully subsidised without restriction. Please note that this listing is NOT a result of awarding a tender. Lipex remains listed and fully subsidised.



New osmotic laxative subsidised

A new osmotic laxative will be subsidised from 1 October 2007. Macrogol 3350 (Movicol) will be subsidised for patients for use as last line oral therapy under Special Authority criteria. See page 20 for further details. Subsidised dispensings will be restricted to a maximum of 60 sachets per prescription. Prescriptions that are written for more than 60 sachets will be eligible for a subsidy for 60 sachets and the balance will not be subsidised.

Colifoam – clarification of dose

We have amended the presentation description for hydrocortisone acetate rectal foam 10%, CFC-Free (Colifoam) as there was some confusion over the dose of the product. The presentation now includes how many applications are in each pack – 14 applications per 21.1 g OP. We believe that some prescribers are prescribing one original pack per dose as they are unsure of the number of doses per pack. We hope that this amendment will help to avoid any further confusion.



Etanercept – named specialists update

The list of named specialists that may apply for Special Authorities for etanercept has been amended. Applications may be made by one of the named specialists listed below, or by a rheumatologist:

Dr Priscilla Campbell-Stokes, Lower Hutt

Dr Anthony Gear, Palmerston North

Dr John Highton, Dunedin

Dr Peter Jones, Rotorua

Dr Archie Kerr, Wellington

Dr Stuart Malcolm, Palmerston North

Dr Maud Meates-Dennis, Christchurch

Dr Peter Moller, Christchurch

Dr John O'Donnell, Christchurch

Dr Sue Rudge, Auckland & Wellington

Dr Raoul Stuart, Auckland

Dr Jackie Yan, Auckland

All prescriptions must be written by a relevant specialist but not necessarily one of those named above.

Tender News

Sole Subsidised Supply changes – effective 1 November 2007

Chemical Name	Presentation; Pack size	Sole Subsidised Supply brand (and supplier)
Ibuprofen	Oral liq 100 mg per 5 ml; 200 ml	Fenpaed (AFT)

Looking Forward

This section is designed to alert both pharmacists and prescribers to possible future changes. It may assist pharmacists to manage stock levels and keep prescribers up-to-date with proposals to change the Pharmaceutical Schedule.

Possible decisions for implementation 1 November 2007

- Diazepam (Stesolid) rectal tubes 5 mg and 10 mg – increased price & subsidy
- Povidone iodine (Riodine) antiseptic soln 10% - decreased price & subsidy
- Quetiapine (Quetapel) tab 25 mg, 100 mg, 200 mg and 300 mg – new listing
- Sodium chloride (Multichem) inj 0.9%, 20 ml – new listing

Sole Subsidised Supply Products – cumulative to October 2007

Generic Name	Presentation	Brand Name	Expiry Date*
Acetazolamide	Tab 250 mg	Diamox	2008
Acipimox	Cap 250 mg	Olbetam	2008
Acitretin	Cap 10 mg & 25 mg	Neotigason	2008
Allopurinol	Tab 100 mg & 300 mg	Progout	2008
Amitriptyline	Tab 10 mg, 25 mg & 50 mg	Amitrip	2008
Amlodipine	Tab 5 mg & 10 mg	Calvasc	2008
Apomorphine hydrochloride	Inj 10 mg per ml, 1 ml	Mayne	2009
Amoxicillin	Cap 250 mg & 500 mg Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Inj 250 mg, 500 mg & 1 g	Apo-Amoxi Ranbaxy Amoxicillin Ranbaxy Amoxicillin Ibiamox	2010 2009 2008
Applicator	Device	Ortho	2008
Aqueous cream	Cream	Multichem	2008
Ascorbic acid	Tab 100 mg	Apo-Ascorbic Acid	2009
Atenolol	Tab 50 mg & 100 mg	Loten	2009
Atropine sulphate	Inj 600 µg, 1 ml Inj 1200 µg, 1 ml Eye drops 1%	AstraZeneca AstraZeneca Atropt	2009 2008
Beclomethasone dipropionate	Metered aqueous nasal spray 50 µg Metered aqueous nasal spray 100 µg	Alanase Alanase	2009
Betamethasone valerate	Scalp app 0.1% Crn 0.1% Oint 0.1%	Beta Scalp Beta Cream Beta Ointment	2009 2008
Bezafibrate	Tab 200 mg	Fibalip	2008
Bisacodyl	Tab 5 mg	Lax-Tab	2010
Brimonidine tartrate	Eye drops 0.2%	AFT	2008
Bromocriptine mesylate	Tab 2.5 mg & 10 mg	Alpha-Bromocriptine	2008
Bupivacaine hydrochloride	Inj 0.5%, 4 ml Inj 0.5%, 8% glucose, 4 ml	Marcain Isobaric Marcain Heavy	2010
Calamine	Lotion BP Crn, aqueous, BP	ABM ABM	2009
Calcitriol	Cap 0.25 µg & 0.5 µg	Calcitriol-AFT	2009
Calcium carbonate	Tab dispersible 2.5 g Tab 1.25 g Tab 1.5 g	Calci-Tab Effervescent Calci-Tab 500 Calci-Tab 600	2008
Calcium folinate	Inj 50 mg	Calcium Folate Ebewe	2008
Cefaclor monohydrate	Cap 250 mg Grans for oral liq 125 mg per 5 ml	Ranbaxy Cefaclor Ranbaxy Cefaclor	2010
Cefazolin sodium	Inj 500 mg & 1 g	m-Cefazolin	2008

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated.

Sole Subsidised Supply Products – cumulative to October 2007

Generic Name	Presentation	Brand Name	Expiry Date*
Ceftriaxone sodium	Inj 500 mg & 1 g	AFT	2008
Cetirizine hydrochloride	Oral liq 1 mg per ml Tab 10 mg	Allerid C Razene	2008
Chloramphenicol	Eye drops 0.5% Eye oint 1%	Chlorsig Chlorsig	2009
Chlorhexidine gluconate	Handrub 1% with ethanol 70%	Orion	2009
	Mouthwash 0.2%	Orion	
	Soln 4%	Orion	2008
Chlorthalidone	Tab 25 mg	Hygroton	2009
Ciprofloxacin	Tab 250 mg, 500 mg & 750 mg	Cipflox	2008
Clarithromycin	Grans for oral liq 125 mg per 5 ml	Klacid	2010
Clindamycin	Cap hydrochloride 150 mg	Dalacin C	2008
	Inj phosphate 150 mg per ml, 4 ml		
Clobetasol propionate	Crn 0.05%	Dermol	2009
	Scalp app 0.05%	Dermol	2008
	Oint 0.05%	Dermol	
Clonazepam	Tab 500 µg & 2 mg	Paxam	2008
Clonidine	TDDS 2.5 mg, 100 µg per day	Catapres-TTS-1	2008
	TDDS 5 mg, 200 µg per day	Catapres-TTS-2	
	TDDS 7.5 mg, 300 µg per day	Catapres-TTS-3	
Clonidine hydrochloride	Tab 25 µg	Dixarit	2008
	Tab 150 µg	Catapres	
	Inj 150 µg per ml, 1 ml	Catapres	
Clotrimazole	Vaginal crm 1% with applicator(s)	Clomazol	2010
	Crn 1%	Clomazol	2008
Colchicine	Tab 500 µg	Colgout	2010
Compound electrolytes	Powder for soln for oral use	Enerlyte	2010
Co-trimoxazole	Oral liq sugar-free trimethoprim 40 mg and sulphamethoxazole 200 mg per 5 ml Tab trimethoprim 80 mg and sulphamethoxazole 400 mg	Trisul	2008
Cyclizine hydrochloride	Tab 50 mg	Nausicalm	2009
Cyclizine lactate	Inj 50 mg per ml, 1 ml	Valoid (AFT)	2008
Cyclophosphamide	Tab 50 mg	Cycloblastin	2010
Cyproterone acetate	Tab 50 mg	Siterone	2009
Dantrolene sodium	Cap 25 mg & 50 mg	Dantrium	2009
Desferrioxamine mesylate	Inj 500 mg	Mayne	2010
Desmopressin	Nasal spray 10 µg per dose	Desmopressin-PH&T	2008
Dexamethasone sodium phosphate	Inj 4 mg per ml, 1 ml	Mayne	2009
	Inj 4 mg per ml, 2 ml		

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated.

Sole Subsidised Supply Products – cumulative to October 2007

Generic Name	Presentation	Brand Name	Expiry Date*
Diaphragm	Range of sizes	Ortho All-flex & Ortho Coil	2008
Diclofenac sodium	Tab EC 25 mg & 50 mg Tab long-acting 75 mg & 100 mg	Apo-Diclo Apo-Diclo SR	2009
Didanosine (DDI)	Cap 125 mg, 200 mg, 250 mg & 400 mg	Videx EC	2009
Dihydrocodeine tartrate	Tab long-acting 60 mg	DHC Continus	2008
Diphenoxylate hydrochloride with atropine sulphate	Tab 2.5 mg with atropine sulphate 25 µg	Diastop	2008
Dipyridamole	Tab long-acting 150 mg	Pytazen SR	2008
Docusate sodium	Tab 50 mg & 120 mg	Coloxyl	2008
Emulsifying ointment BP	Ointment	AFT	2008
Enalapril	Tab 5 mg, 10 mg & 20 mg	m-Enalapril	2009
Ergometrine maleate	Inj 500 µg per ml, 1 ml	Mayne	2009
Ergotamine tartrate with caffeine	Tab 1 mg with caffeine 100 mg	Cafergot	2009
Erythromycin ethyl succinate	Grans for oral liq 200 mg per 5 ml Grans for oral liq 400 mg per 5 ml	E-Mycin E-Mycin	2008
Ethambutol hydrochloride	Tab 400 mg	Myambutol	2008
Ethinylestradiol	Tab 10 µg	New Zealand Medical and Scientific	2009
Ethinylestradiol with norethisterone	Tab 35 µg with norethisterone 500 µg Tab 35 µg with norethisterone 1 mg Tab 35 µg with norethisterone 1 mg and 7 inert tab Tab 35 µg with norethisterone 500 µg and 7 inert tab	Brevinor 21 Brevinor 1/21 Brevinor 1/28 Norimin	2010 2008
Etoposide	Cap 50 mg & 100 mg	Vepesid	2009
Flucloxacillin sodium	Cap 250 mg & 500 mg Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml	Staphlex AFT AFT	2009
Fluconazole	Cap 50 mg, 150 mg & 200 mg	Pacific	2008
Fluocortolone caproate with fluocortolone pivalate and cinchocaine	Oint 950 µg, with fluocortolone pivalate 920 µg, and cinchocaine hydrochloride 5 mg per g Suppos 630 µg, with fluocortolone pivalate 610 µg, and cinchocaine hydrochloride 1 mg	Ultraproct Ultraproct	2010
Fluorometholone	Eye drops 0.1%	Flucon	2009
Fluphenazine decanoate	Inj 12.5 mg per 0.5 ml, 0.5 ml Inj 25 mg per ml, 1 ml Inj 100 mg per ml, 1 ml	Modecate Modecate Modecate	2008

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated.

Sole Subsidised Supply Products – cumulative to October 2007

Generic Name	Presentation	Brand Name	Expiry Date*
Folic Acid	Tab 0.8 mg & 5 mg	Apo-Folic Acid	2009
Fusidic acid	Crn 2% & Oint 2%	Foban	2010
Gentamicin sulphate	Inj 40 mg per ml, 2 ml	Pfizer	2009
Gliclazide	Tab 80 mg	Apo-Gliclazide	2008
Glipizide	Tab 5 mg	Minidiab	2008
Haloperidol	Oral liq 2 mg per ml Tab 500 µg, 1.5 mg & 5 mg Inj 5 mg per ml, 1 ml	Serenace Serenace Serenace	2010 2009
Haloperidol decanoate	Inj 50 mg per ml, 1 ml Inj 100 mg per ml, 1 ml	Haldol Haldol Concentrate	2008
Heparinised saline	Inj 10 iu per ml, 5 ml	AstraZeneca	2009
Hydrocortisone	Tab 5 mg & 20 mg Powder 25 g	Douglas m-Hydrocortisone	2009 2008
Hydrocortisone acetate	Rectal foam 10%, CFC-Free	Colifoam	2009
Hydrocortisone with wool fat and mineral oil	Lotn 1% with wool fat hydrous 3% and mineral oil	DP Lotn HC	2008
Hyoscine N-butylbromide	Tab 10 mg Inj 20 mg	Gastrosoothe Buscopan	2008
Hypromellose	Eye drops 0.3% Eye drops 0.5%	Poly-Tears Methopt	2008
Ibuprofen	Tab 200 mg	I-Profen	2008
Imipramine hydrochloride	Tab 10 mg & 25 mg	Tofranil	2009
Indapamide	Tab 2.5 mg	Napamide	2009
Indomethacin	Cap 25 mg & 50 mg	Rheumacin	2008
Ipratropium bromide	Nebuliser soln, 250 µg per ml, 1 ml Nebuliser soln, 250 µg per ml, 2 ml Aerosol inhaler, 20 µg per dose CFC-free	Ipratropium Steri-Neb Ipratropium Steri-Neb Atrovent	2010 2008
Isosorbide mononitrate	Tab long-acting 60 mg	Duride	2009
Isotretinoin	Cap 10 mg Cap 20 mg	Isotane 10 Isotane 20	2009
Itraconazole	Cap 100 mg	Sporanox	2010
Ketoconazole	Shampoo 2%	Ketopine	2008
Levobunolol	Eye drops 0.25% & 0.5%	Betagan	2010
Levodopa with benserazide	Cap 50 mg with benserazide 12.5 mg Tab dispersible 50 mg with benserazide 12.5 mg Cap 100 mg with benserazide 25 mg Cap long-acting 100 mg with benserazide 25 mg Cap 200 mg with benserazide 50 mg	Madopar 62.5 Madopar Dispersible Madopar 125 Madopar HBS Madopar 250	2009

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated.

Sole Subsidised Supply Products – cumulative to October 2007

Generic Name	Presentation	Brand Name	Expiry Date*
Lignocaine hydrochloride	Inj 0.5%, 5 ml Inj 1%, 5 ml Inj 1%, 20 ml	Xylocaine Xylocaine Xylocaine	2010
Lignocaine with prilocaine	Crn 2.5% with prilocaine 2.5%; 30 g OP Crn 2.5% with prilocaine 2.5%; 5 g	EMLA EMLA	2010
Lisinopril	Tab 5 mg, 10 mg & 20 mg	Arrow-Lisinopril	2009
Loperamide hydrochloride	Tab 2 mg	Nodia	2010
Loratadine	Oral liq 1 mg per ml	Lorapaed	2010
Lorazepam	Tab 1 mg & 2.5 mg	Ativan	2009
Magnesium sulphate	Inj 49.3%	Mayne	2009
Maldison	Shampoo 1%	A-Lices	2010
Maprotiline hydrochloride	Tab 25 mg & 75 mg	Ludiomil	2009
Medroxyprogesterone acetate	Tab 2.5 mg, 5 mg, 10 mg, 100 mg & 200 mg	Provera	2010
Mesalazine	Enema 1 g per 100 ml	Pentasa	2009
Methadone hydrochloride	Powder 1 g	AFT	2009
Methotrexate	Tab 2.5 mg & 10 mg Inj 100 mg per ml, 5 ml Inj 100 mg per ml, 10 ml Inj 100 mg per ml, 50 ml	Methoblastin Methotrexate Ebewe Methotrexate Ebewe Methotrexate Ebewe	2009 2008
Methylodopa	Tab 125 mg, 250 mg & 500 mg	Prodopa	2008
Methylphenidate hydrochloride	Tab long-acting 20 mg Tab 5 mg & 20 mg Tab 10 mg	Rubifen SR Rubifen Rubifen	2009
Methylprednisolone	Tab 4 mg & 100 mg	Medrol	2009
Methylprednisolone aceponate	Crn 0.1% and oint 0.1%	Advantan	2009
Methylprednisolone acetate	Inj 40 mg per ml, 1 ml	Depo-Medrol	2008
Methylprednisolone acetate with lignocaine	Inj 40 mg per ml with lignocaine 1 ml	Depo-Medrol with Lidocaine	2008
Methylprednisolone sodium succinate	Inj 40 mg per ml, 1 ml Inj 62.5 mg per ml, 1 ml Inj 500 mg & 1 g	Solu-Medrol Solu-Medrol Solu-Medrol	2009
Metoclopramide hydrochloride	Inj 5 mg per ml, 2 ml	Pfizer	2008
Metoprolol tartrate	Tab long-acting 200 mg	Slow-Lopressor	2009
Metyrapone	Cap 250 mg	Metopirone	2009
Mexiletine hydrochloride	Cap 50 mg & 200 mg	Mexitil	2008
Miconazole nitrate	Crn 2%	Multichem	2008
Midodrine	Tab 2.5 mg & 5 mg	Gutron	2009

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated.

Sole Subsidised Supply Products – cumulative to October 2007

Generic Name	Presentation	Brand Name	Expiry Date*
Misoprostol	Tab 200 µg	Cytotec	2009
Moclobemide	Tab 150 mg & 300 mg	Apo-Moclobemide	2009
Morphine hydrochloride	Oral liq 1 mg per ml Oral liq 2 mg per ml Oral liq 5 mg per ml Oral liq 10 mg per ml	RA-Morph RA-Morph RA-Morph RA-Morph	2009
Morphine sulphate	Inj 5 mg per ml, 1 ml Inj 15 mg per ml, 1 ml Cap long-acting 10 mg, 30 mg, 60 mg, 100 mg & 200 mg Tab immediate release 10 mg & 20 mg	Mayne Mayne m-Eslon Sevredol	2009
Morphine tartrate	Inj 80 mg per ml, 1.5 ml & 5 ml	Mayne	2009
Nadolol	Tab 40 mg & 80 mg	Apo-Nadolol	2010
Naltrexone hydrochloride	Tab 50 mg	ReVia	2010
Naphazoline hydrochloride	Eye drops 0.1%	Naphcon Forte	2008
Naproxen	Tab 250 mg	Noflam 250	2009
	Tab 500 mg	Noflam 500	
	Tab long-acting 750 mg	Naprosyn SR 750	2008
	Tab long-acting 1000 mg	Naprosyn SR 1000	
Neostigmine	Inj 2.5 mg per ml, 1 ml	AstraZeneca	2010
Nevirapine	Oral suspension 10 mg per ml	Viramune Suspension	2009
Nicotinic acid	Tab 50 mg & 500 mg	Apo-Nicotinic Acid	2009
Nifedipine	Tab long-acting 20 mg	Nyefax Retard	2009
Nonoxynol-9	Jelly 2%	Gynol II	2008
Norethisterone	Tab 350 µg	Noriday 28	2009
	Tab 5 mg	Primolut-N	2008
Norfloxacin	Tab 400 mg	Arrow-Norfloxacin	2008
Nortriptyline	Tab 10 mg & 25 mg	Norpress	2008
Nystatin	Cap 500,000 u	Nilstat	2010
	Tab 500,000 u	Nilstat	
	Vaginal crm 100,000 u per 5 g with applicators	Nilstat	2009
	Oral liq 100,000 u per ml	Nilstat	2008
Ondansetron	Tab 4 mg & 8 mg	Zofran	2010
	Tab disp 4 mg & 8 mg	Zofran Zydis	
Oxytocin	Inj 5 iu per ml, 1 ml	Syntocinon	2009
	Inj 10 iu per ml, 1 ml	Syntocinon	
	Inj 5 iu with ergometrine maleate 500 µg per ml, 1 ml	Syntometrine	

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated.

Sole Subsidised Supply Products – cumulative to October 2007

Generic Name	Presentation	Brand Name	Expiry Date*
Pamidronate disodium	Inj 3 mg per ml, 5 ml Inj 3 mg per ml, 10 ml Inj 6 mg per ml, 10 ml	Pamisol Pamisol Pamisol	2008
Paracetamol	Tab 500 mg Suppos 125 mg & 250 mg Oral liq 120 mg per 5 ml Oral liq 250 mg per 5 ml	Panadol Panadol Junior Parapaed Six Plus Parapaed	2008
Paracetamol with codeine	Tab 500 mg with 8 mg codeine	Codalgin	2008
Paraffin liquid with soft white paraffin	Eye oint with soft white paraffin	Laci-Lube	2010
Paroxetine hydrochloride	Tab 20 mg	Loxamine	2010
Pergolide	Tab 0.25 mg & 1 mg	Permax	2008
Perhexiline maleate	Tab 100 mg	Pexsig	2009
Phenoxymethylpenicillin (Penicillin V)	Cap potassium salt 250 mg Cap potassium salt 500 mg	Cilicaine VK Cilicaine VK	2010
Pilocarpine	Eye drops 0.5%, 1%, 2%, 4% & 6%	Pilopt	2008
Poloxamer	Oral drops 10%	Coloxyl	2008
Potassium chloride	Tab long-acting 600 mg Inj 75 mg per ml, 10 ml Inj 150 mg per ml, 10 ml	Span-K AstraZeneca AstraZeneca	2009 2008
Prednisone	Tab 1 mg, 2.5 mg, 5 mg & 20 mg	Apo-Prednisone	2008
Pregnancy tests - HCG urine	Cassette	MDS Quick Card	2009
Procaine penicillin	Inj 1.5 mega u	Cilicaine	2008
Promethazine hydrochloride	Tab 10 mg & 25 mg	Allersoothe	2008
Pyridoxine hydrochloride	Tab 50 mg	Apo-Pyridoxine	2009
Quinapril	Tab 5 mg, 10 mg & 20 mg	Accupril	2008
Quinapril with hydrochlorothiazide	Tab 10 mg with hydrochlorothiazide 12.5 mg Tab 20 mg with hydrochlorothiazide 12.5 mg	Accuretic 10 Accuretic 20	2008
Quinine sulphate	Tab 200 mg Tab 300 mg	Q 200 Q 300	2009
Ranitidine hydrochloride	Tab 150 mg & 300 mg	Arrow Ranitidine	2008
Rifabutin	Cap 150 mg	Mycobutin	2010
Roxithromycin	Tab 150 mg & 300 mg	Arrow-Roxithromycin	2009
Salbutamol	Nebuliser soln 1 mg per ml, 2.5 ml Nebuliser soln 2 mg per ml, 2.5 ml Oral liq 2 mg per 5 ml	Asthalin Asthalin Salapin	2009 2009 2010
Salbutamol with ipratropium bromide	Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg	Duolin	2009

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated.

Sole Subsidised Supply Products – cumulative to October 2007

Generic Name	Presentation	Brand Name	Expiry Date*
Selegiline hydrochloride	Tab 5 mg	Apo-Selegiline	2009
Sodium chloride	Inj 0.9%, 5 ml & 10 ml	AstraZeneca	2009
Sodium citro-tartrate	Grans eff 4 g sachets	Ural	2010
Sodium cromoglycate	Nasal spray 4% Eye drops 2%	Rex Cromolux	2009 2008
Sulphasalazine	Tab 500 mg Tab EC 500 mg	Salazopyrin Salazopyrin EN	2009
Syrup (pharmaceutical grade)	Liq	Midwest	2010
Tar with triethanolamine lauryl sulphate and fluorescein	Soln 2.3% with triethanolamine lauryl sulphate and fluorescein sodium	Pinetarsol	2008
Temazepam	Tab 10 mg	Normison	2008
Terbinafine	Tab 250 mg	Apo-Terbinafine	2008
Timolol maleate	Tab 10 mg	Apo-Timol	2009
Thiamine hydrochloride	Tab 50 mg	Apo-Thiamine	2009
Triamcinolone acetonide	Crn & Oint 0.02% Dental Paste USP 0.1%	Aristocort Oracort	2008
Triamcinolone acetonide with gramicidin, neomycin and nystatin	Ear drops 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 mcg per g	Kenacomb	2009
	Oint 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 µg per g	Kenacomb	2008
Triazolam	Tab 125 µg	Hypam Hypam	2008
	Tab 250 µg		
Trimethoprim	Tab 300 mg	TMP	2008
Trimipramine maleate	Cap 25 mg & 50 mg	Tripres	2008
Urea	Crn 10%	Nutraplus	2008
Ursodeoxycholic acid	Cap 300 mg	Actigall	2008
Vancomycin hydrochloride	Inj 50 mg per ml, 10 ml	Pacific	2008
Verapamil hydrochloride	Tab long-acting 120 mg	Verpamil SR	2008
Vincristine sulphate	Inj 1 mg per ml, 1 ml	Mayne Mayne	2009
	Inj 1 mg per ml, 2 ml		
Vitamins	Tab (BPC cap strength)	Healtheries	2009
Vitamin B complex	Tab, strong, BPC	Apo-B-Complex	2009
Water	Purified for injection 20 ml	Multichem	2009
Zinc and castor oil	Oint BP	Multichem	2008
Zinc sulphate	Cap 220 mg	Zincaps	2008
Zopiclone	Tab 7.5 mg	Apo-Zopiclone	2008

October changes are in bold type

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated.

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

New Listings

Effective 1 October 2007

25	MESALAZINE Suppos 1 g	50.96	28	✓ Pentasa
27	OMEPRAZOLE * Cap 10 mg	2.99	28	✓ Dr Reddy's Omeprazole
	* Cap 20 mg	4.27	28	✓ Dr Reddy's Omeprazole
	* Cap 40 mg	5.01	28	✓ Dr Reddy's Omeprazole
34	LACTULOSE – Only on a prescription * Oral liq 10 g per 15 ml	6.65	1,000 ml	✓ Duphalac
34	MACROGOL 3350 – Special Authority see SA0891 – Retail pharmacy Powder 13.125 g, sachets – not more than 60 sachets per prescription.....	18.14	30	✓ Movicol
▶ SA0891] Special Authority for Subsidy				
Initial application by any relevant practitioner. Approvals valid for 6 months where the patient has problematic constipation requiring intervention with a per rectal preparation despite an adequate trial of other oral pharmacotherapies including lactulose where lactulose is not contraindicated.				
Renewal from any relevant practitioner. Approvals valid for 12 months where the patient is compliant and is continuing to gain benefit from treatment.				
49	SIMVASTATIN – See prescribing guideline * Tab 10 mg	2.31	30	✓ SimvaRex
	* Tab 20 mg	2.81	30	✓ SimvaRex
	* Tab 40 mg	4.98	30	✓ SimvaRex
98	IBUPROFEN – Additional subsidy by Special Authority see SA0291 – Retail pharmacy * Tab 600 mg	1.60 (6.84)	30	Brufen
107	CITALOPRAM HYDROBROMIDE * Tab 20 mg	3.50	28	✓ Citalopram - Rex
121	MIDAZOLAM Inj 1 mg per ml, 5 ml	12.65 (14.73)	10	Pfizer
	Inj 5 mg per ml, 3 ml	14.00 (19.64)	5	Pfizer
146	BUDESONIDE WITH EFORMOTEROL – Special Authority see SA0838 – Retail pharmacy Aerosol inhaler 100 µg with eformoterol fumarate 6 µg	55.00	120 dose OP	✓ Symbicort Rapihaler
	Aerosol inhaler 200 µg with eformoterol fumarate 6 µg	60.00	120 dose OP	✓ Symbicort Rapihaler

Check your Schedule for full details Schedule page ref	Subsidy (Mnfr's price) \$	Per	Brand or Generic Mnfr ✓ fully subsidised
---	---------------------------------	-----	--

New Listings - effective 1 October 2007 (continued)

148	IPRATROPIUM BROMIDE Aqueous nasal spray, 0.03%	12.66	30 ml OP	✓ Apo-Ipravent
180	SOYA INFANT FORMULA – Special Authority see SA0604 – Retail pharmacy Powder	6.34 (19.57)	900 g OP	S26 Soy

Effective 17 September 2007

144	LORATADINE * Tab 10 mg	3.58	100	✓ Loraclear Hayfever Relief
		8.50	30	✓ Loraclear Hayfever Relief

Effective 1 September 2007

86	AZITHROMYCIN – Subsidy by endorsement a) Maximum of 2 tab per prescription b) Available on a PSO c) Subsidised only if prescribed for patients with uncomplicated urethritis or cervicitis proven or presumed to be due to Chlamydia trachomatis and their sexual contacts and prescription or PSO is endorsed accordingly. Tab 500 mg	9.90	2 OP	✓ Arrow-Azithromycin
104	METHADONE HYDROCHLORIDE a) Only on a controlled drug form b) No patient co-payment payable c) Extemporaneously compounded methadone will only be reimbursed at the rate of the cheapest form available (methadone powder, not methadone tablets). d) For methadone hydrochloride oral liquid refer, page 159 Tab 5 mg	2.10	10	✓ PSM
106	OXYCODONE HYDROCHLORIDE a) Only on a controlled drug form b) No patient co-payment payable Inj 10 mg per ml, 1 ml	14.40	5	✓ OxyNorm
	Inj 10 mg per ml, 2 ml	28.80	5	✓ OxyNorm
	‡ Oral liq 5 mg per 5 ml	11.20	250 ml	✓ OxyNorm

Prescribing Guideline

Prescribers should note that oxycodone is significantly more expensive than long-acting morphine sulphate and clinical advice suggests that it is reasonable to consider this as a second-line agent to be used after morphine.

▲ Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

* Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

Changes to Restrictions

Effective 1 October 2007

25	HYDROCORTISONE ACETATE Rectal foam 10 %, CFC-Free (14 applications)	21.10	21.1 g OP	✓ Colifoam
55	METOPROLOL SUCCINATE * Tab long-acting 23.75 mg – Higher subsidy of \$6.20 per 30 with Endorsement	5.20 (6.20)	30	Betaloc CR
	* Tab long-acting 47.5 mg – Higher subsidy of \$7.80 per 30 with Endorsement	6.50 (7.80)	30	Betaloc CR
	* Tab long-acting 95 mg – Higher subsidy of \$13.20 per 30 with Endorsement	11.20 (13.20)	30	Betaloc CR
	* Tab long-acting 190 mg – Higher subsidy of \$21.00 per 30 with Endorsement	20.25 (21.00)	30	Betaloc CR

Additional subsidy by endorsement is available for patients who:

- a) were being prescribed metoprolol succinate prior to 1 October 2007; or
- b) have experienced a myocardial infarction.

The prescription must be endorsed accordingly

Note – Repeats for Betaloc CR tab long-acting will be fully subsidised where the initial dispensing was before 1 October 2007.

88	PHENOXYMETHYLPENICILLIN (PENICILLIN V) Grans for oral liq benzathine 125 mg per 5 ml – Available on a PSO	1.68	100 ml	✓ AFT
	Grans for oral liq benzathine 250 mg per 5 ml – Available on a PSO	1.82	100 ml	✓ AFT

117 QUETIAPINE – Subsidy by endorsement
Subsidised for:

- 1) patients presenting with first episode schizophrenia or related psychoses, or manic episodes associated with bipolar disorder; and
- 2) patients suffering from schizophrenia or related psychoses, or manic episodes associated with bipolar disorder, after a trial of an effective dose of risperidone that has been discontinued because of unacceptable side effects or inadequate response.

Initial prescription must be written by a relevant specialist. Subsequent prescriptions may be written by a general practitioner. The prescription must be endorsed "certified condition".

Tab 25 mg	46.20	60	✓ Seroquel
Tab 100 mg	92.40	60	✓ Seroquel
Tab 200 mg	158.76	60	✓ Seroquel
Tab 300 mg	267.12	60	✓ Seroquel

134 MYCOPHENOLATE MOFETIL – Special Authority see SA0893 0798 – Hospital pharmacy [HP3]

Tab 500 mg	206.66	50	✓ Cellcept
Cap 250 mg	206.66	100	✓ Cellcept
Powder for oral liq 1 g per 5 ml – Subsidy by endorsement ...	285.00	165 ml OP	✓ Cellcept

Mycophenolate powder for oral liquid is subsidised only for patients unable to swallow tablets and capsules, and when the prescription is endorsed accordingly.

continued...

Patients pay a manufacturer's surcharge when the Manufacturer's Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29
‡ safety cap reimbursed **Sole Subsidised Supply**

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

Changes to Restrictions - effective 1 October 2007 (continued)

continued...

		Subsidy (Mnfr's price) \$ Per	Brand or Generic Mnfr ✓ fully subsidised
SA0893 0798 Special Authority for Subsidy			
Initial application only from a relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria:			
Any of the following:			
1 Renal transplant recipient; or			
2 Heart transplant recipient; or			
3 Patient has an organ transplant and has severe tophaceous gout making azathioprine unsuitable.			
Renewal only from a relevant specialist. Approvals valid without further renewal unless notified where the patient had a previous Special Authority approval and was receiving mycophenolate prior to 1 October 2005.			
150	ACICLOVIR * Eye oint 3% —Retail pharmacy-Specialist.....	37.53	4.5 g OP ✓ Zovirax
150	CIPROFLOXACIN Eye Drops 0.3% —Retail pharmacy-Specialist prescription 1) Specialist must be an ophthalmologist. 2) For treatment of bacterial keratitis or severe bacterial conjunctivitis resistant to chloramphenicol.	12.43	5 ml OP ✓ Ciloxan
150	DEXAMETHASONE WITH FRAMYCETIN AND GRAMICIDIN Retail Pharmacy —Specialist when used in the treatment of eye conditions: Ear/Eye drops 500 µg with framycetin sulphate 5 mg and gramicidin 50 µg per ml.....	4.50 (9.27)	8 ml OP Sofradex
150	GENTAMICIN SULPHATE Eye drops 0.3% —Retail pharmacy-Specialist.....	11.40	5 ml OP ✓ Genoptic
151	BETAXOLOL HYDROCHLORIDE —Retail pharmacy-Specialist * Eye drops 0.25% * Eye drops 0.5%	11.80 7.50	5 ml OP ✓ Betoptic S 5 ml OP ✓ Betoptic
151	DEXAMETHASONE —Retail pharmacy-Specialist * Eye oint 0.1% * Eye drops 0.1 %	5.86 4.50	3.5 g OP ✓ Maxidex 5 ml OP ✓ Maxidex
151	DEXAMETHASONE WITH NEOMYCIN AND POLYMYXIN B SULPHATE —Retail pharmacy-Specialist * Eye oint 0.1% with neomycin sulphate 0.35% and polymyxin B sulphate 6,000 u per g * Eye drops 0.1% with neomycin sulphate 0.35% and polymyxin B sulphate 6,000 u per ml	5.39 4.50	3.5 g OP ✓ Maxitrol 5 ml OP ✓ Maxitrol
151	DICLOFENAC SODIUM * Eye drops 1 mg per ml —Retail pharmacy-Specialist.....	13.80	5 ml OP ✓ Voltaren Ophtha
151	FLUOROMETHOLONE —Retail pharmacy-Specialist * Eye drops 0.1%	4.30	5 ml OP ✓ Flucon
151	LEVOBUNOLOL —Retail pharmacy-Specialist * Eye drops 0.25% * Eye drops 0.5 %	7.00 7.00	5 ml OP ✓ Betagan 5 ml OP ✓ Betagan

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

* Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

Changes to Restrictions - effective 1 October 2007 (continued)

151	PREDNISOLONE ACETATE —Retail pharmacy—Specialist				
	* Eye drops 0.12%	4.50	5 ml OP		
		(7.53)		Pred Mild	
	* Eye drops 1%	4.50	5 ml OP		
		(9.44)		Pred Forte	
151	TOBRAMYCIN				
	Eye oint 0.3% —Retail pharmacy—Specialist.....	10.45	3.5 g OP	✓Tobrex	
	Eye drops 0.3% —Retail pharmacy—Specialist.....	11.48	5 ml OP	✓Tobrex	
152	BRIMONIDINE TARTRATE —Retail pharmacy—Specialist				
	* Eye Drops 0.2%	8.95	5 ml OP	✓AFT	
152	DORZOLAMIDE HYDROCHLORIDE —Retail pharmacy—Specialist				
	* Eye drops 2%	9.77	5 ml OP		Trusopt
		(13.95)			
152	DORZOLAMIDE HYDROCHLORIDE WITH TIMOLOL MALEATE —Retail pharmacy—Specialist				
	* Eye drops 2% with timolol maleate 0.5%	18.50	5 ml OP	✓Cosopt	
152	TIMOLOL MALEATE —Retail pharmacy—Specialist				
	* Eye drops 0.25%	2.37	5 ml OP	✓Apo-Timop	
	* Eye drops 0.25%, gel forming	5.30	2.5 ml OP	✓Timoptol XE	
	* Eye drops 0.5%	2.29	5 ml OP	✓Apo-Timop	
	* Eye drops 0.5%, gel forming	5.78	2.5 ml OP	✓Timoptol XE	
153	BRIMONIDINE TARTRATE WITH TIMOLOL MALEATE —Retail pharmacy—Specialist				
	▲ Eye drops 0.2% with timolol maleate 0.5%	18.50	5 ml OP	✓Combigan	
153	PILOCARPINE				
	* Eye drops 2% single dose – Special Authority see SA0895 0121				
	– Hospital pharmacy [HP3]	31.95	20 dose		Minims
		(32.72)			

▶ SA0895 0121 Special Authority for Subsidy

Initial application from any **relevant practitioner** ~~medical practitioner~~. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- 1 Patient has to use an unpreserved solution due to an allergy to the preservative; or
- 2 Patient wears soft contact lenses.

Note: Minims for a general practice are considered to be “tools of trade” and are not approved as special authority items.

Renewal from any **relevant practitioner** ~~medical practitioner~~. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

164 FAT

▶ SA0899 0580 Special Authority for Subsidy

Initial application — (Inborn errors of metabolism) only from a relevant specialist. Approvals valid for 3 years where the patient has inborn errors of metabolism.

Initial application — (Indications other than inborn errors of metabolism) only from a relevant specialist.

Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 failure to thrive **where other high calorie products are inappropriate or inadequate**; or

continued...

Patients pay a manufacturer's surcharge when the Manufacturer's Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29
‡ safety cap reimbursed **Sole Subsidised Supply**

Changes to Restrictions - effective 1 October 2007 (continued)

continued...

- 2 growth deficiency; or
- 3 bronchopulmonary dysplasia; or
- 4 fat malabsorption; or
- 5 lymphangiectasia; or
- 6 short bowel syndrome; or
- 7 infants with necrotising enterocolitis; or
- 8 biliary atresia.

Renewal — (Inborn errors of metabolism) only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the specialist and date contacted.

Renewal — (Indications other than inborn errors of metabolism) only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the specialist and date contacted.

168 PAEDIATRIC PRODUCTS

▶ SA0896 ~~0599~~ Special Authority for Subsidy

Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 infant aged one to **eight six** years; and
- 2 Any of the following:
 - 2.1 any condition causing malabsorption; or
 - 2.2 failure to thrive; or
 - 2.3 increased nutritional requirements; and
- 3 Either:
 - 3.1 The product is to be used as a supplement (maximum 500 ml per day); or
 - 3.2 The product is to be used as a complete diet.

Renewal only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:
 - 2.1 The product is to be used as a supplement (maximum 500 ml per day); or
 - 2.2 The product is to be used as a complete diet; and
- 3 General Practitioners must include the name of the specialist and date contacted.

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

Changes to Restrictions - effective 1 September 2007

113	ONDANSETRON – Hospital pharmacy [HP3] Retail pharmacy-Specialist			
	a) Maximum of 12 tab per prescription; can be waived by Special Authority see SA0887 below			
	b) Maximum of 6 tab per dispensing; can be waived by Special Authority see SA0887 below			
	c) Not more than one prescription per month; can be waived by Special Authority see SA0887 below.			
	Tab 4 mg	17.18	10	✓Zofran
	Tab disp 4 mg	17.18	10	✓Zofran Zydis
	Tab 8 mg	33.89	20	✓Zofran
	Tab disp 8 mg	20.43	10	✓Zofran Zydis

➔ **SA0887** Special Authority for Waiver of Rule

Initial application from any relevant practitioner. Approvals valid for 12 months where patient is undergoing prolonged treatment with highly emetogenic chemotherapy and/or highly emetogenic radiation therapy for the treatment of malignancy.

Renewal from any relevant practitioner. Renewals valid for 12 months where patient is undergoing prolonged treatment with highly emetogenic chemotherapy and/or highly emetogenic radiation therapy for the treatment of malignancy.

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

Changes to Subsidy and Manufacturer's Price

Effective 1 October 2007

25	MESALAZINE (↓ subsidy)				
	Tab 400 mg – Retail pharmacy-Specialist	49.50	100	✓ Asacol	
	Suppos 500 mg	25.20	20	✓ Asacol	
47	DEXTROSE WITH ELECTROLYTES (↓ subsidy)				
	Soln with electrolytes.....	3.33	500 ml OP		Plasma-Lyte Oral
		(3.44)			
		6.30	946 ml OP		Pedialyte - Fruit
		(6.66)			
48	COLESTIPOL HYDROCHLORIDE (↑ subsidy)				
	Sachets 5 g	16.17	30	✓ Colestid	
51	CAPTOPRIL (↑ subsidy)				
	* Tab 12.5 mg	10.40	500	✓ Apo-Captopril	
	* Tab 25 mg	13.40	500	✓ Apo-Captopril	
	* Tab 50 mg	19.00	500	✓ Apo-Captopril	
54	DIGOXIN (↑ subsidy)				
	* Tab 62.5 µg – Available on a PSO	6.94	250	✓ Lanoxin PG	
	* Tab 250 µg – Available on a PSO	15.13	250	✓ Lanoxin	
	*‡ Oral liq 50 µg per ml	16.60	60 ml	✓ Lanoxin	
55	METOPROLOL SUCCINATE (↑ price and alternate subsidy)				
	* Tab long-acting 23.75 mg – Higher subsidy of \$6.20 per 30 with Endorsement	5.20 (6.20)	30		Betaloc CR
	* Tab long-acting 47.5 mg – Higher subsidy of \$7.80 per 30 with Endorsement	6.50 (7.80)	30		Betaloc CR
	* Tab long-acting 95 mg – Higher subsidy of \$13.20 per 30 with Endorsement	11.20 (13.20)	30		Betaloc CR
	* Tab long-acting 190 mg – Higher subsidy of \$21.00 per 30 with Endorsement.....	20.25 (21.00)	30		Betaloc CR
	Additional subsidy by endorsement is available for patients who:				
	a) were being prescribed metoprolol succinate prior to 1 October 2007; or				
	b) have experienced a myocardial infarction.				
	The prescription must be endorsed accordingly				
	Note – Repeats for Betaloc CR tab long-acting will be fully subsidised where the initial dispensing was before 1 October 2007.				
55	METOPROLOL TARTRATE (↑ subsidy)				
	* Tab 50 mg	16.50	100	✓ Lopresor	
65	POVIDONE IODINE (↓ price)				
	Oint 10%	2.88	25 g OP	✓ Betadine	

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

* Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref	Subsidy (Mnfr's price) \$	Per	Brand or Generic Mnfr ✓ fully subsidised
---	---------------------------------	-----	--

Changes to Subsidy and Manufacturer's Price - effective 1 October 2007 (continued)

65	POVIDONE IODINE (↓ subsidy) Antiseptic soln 10%	6.20	500 ml	✓ Betadine
73	OXYBUTYNIN (↑ subsidy) * Oral liq 5 mg per 5 ml	50.40	473 ml OP	✓ Apo-Oxybutynin
80	THYROXINE (↑ subsidy) * Tab 50 µg	48.14	1,000	✓ Eltroxin
	‡ Safety cap for extemporaneously compounded oral liquid preparations. * Tab 100 µg	50.39	1,000	✓ Eltroxin
	‡ Safety cap for extemporaneously compounded oral liquid preparations.			
88	PHENOXYMETHYLPENICILLIN (PENICILLIN V) (↑ subsidy) Grans for oral liq 125 mg per 5 ml – Available on a PSO	1.68	100 ml	✓ AFT
	Grans for oral liq 250 mg per 5 ml – Available on a PSO	1.82	100 ml	✓ AFT
89	COLISTIN SULPHOMETHATE – Hospital pharmacy [HP3]-Specialist – Subsidy by endorsement (↑ subsidy) Only if prescribed for dialysis or cystic fibrosis patient and the prescription is endorsed accordingly. Inj 150 mg	65.00	1	✓ Colistin-Link
89	FUSIDIC ACID (↑ subsidy) Tab 250 mg – Hospital pharmacy [HP3]-Specialist	43.67	12	✓ Fucidin
117	QUETIAPINE (↓ subsidy) Tab 25 mg	46.20	60	✓ Seroquel
	Tab 100 mg	92.40	60	✓ Seroquel
	Tab 200 mg	158.76	60	✓ Seroquel
	Tab 300 mg	267.12	60	✓ Seroquel
130	PACLITAXEL – PCT only – Specialist – Special Authority SA0881 (↓ subsidy) Inj 30 mg	90.00	1	✓ Taxol
	Inj 100 mg	299.70	1	✓ Taxol
	Inj 1 mg for ECP	3.29	1 mg	✓ Baxter
140	INTERFERON BETA-1-BETA – Special Authority SA0855 (↓ subsidy) Inj 8 million iu per 1 ml	1270.23	15	✓ Betaferon

Effective 1 September 2007

29	METFORMIN HYDROCHLORIDE (↓ subsidy) * Tab 500 mg	9.75	500	✓ Metomin
	* Tab 850 mg	8.00	250	✓ Metomin

Check your Schedule for full details Schedule page ref	Subsidy (Mnfr's price) \$	Per	Brand or Generic Mnfr ✓ fully subsidised
---	---------------------------------	-----	--

Changes to Subsidy and Manufacturer's Price - effective 1 September 2007 (continued)

47	WATER (↓ subsidy) 1) On a prescription or Practitioner's Supply Order only when on the same form as an injection listed in the Pharmaceutical Schedule requiring a solvent or diluent; or 2) On a bulk supply order; or 3) When used in the extemporaneous compounding of eye drops.			
	Purified for inj 5 ml – Available on a PSO	9.31	50	✓ AstraZeneca
	Purified for inj 10 ml – Available on a PSO	10.38	50	✓ AstraZeneca
66	MALATHION (↓ subsidy) Liq 0.5%.....	4.99 (5.80)	200 ml	AFT
67	HYDROCORTISONE BUTYRATE (↑ subsidy) Scalp lotn 0.1%	7.52	100 ml OP	✓ Locoid
96	NITROFURANTOIN (↑ subsidy) * Tab 50 mg	17.20	100	✓ Nifuran
	* Tab 100 mg	29.40	100	✓ Nifuran
116	LITHIUM CARBONATE (↑ subsidy) Tab long-acting 400 mg	15.45	100	✓ Priadel
154	PHENYLEPHRINE HYDROCHLORIDE (↑ subsidy) * Eye drops 0.12%	4.47	15 ml OP	✓ Prefrin

Changes to Section G: Safety Cap Medicines

Effective 1 September 2007

OXYCODONE HYDROCHLORIDE Oral liq 5 mg per 5 ml	OxyNorm
---	---------

Changes to Sole Subsidised Supply

Effective 1 October 2007

For the list of new Sole Subsidised Supply products effective 1 October 2007 refer to the bold entries in the cumulative Sole Subsidised Supply table pages 12-19.

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

* Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

Delisted Items

Effective 1 October 2007

77	TESTOSTERONE ENANTHATE – Retail pharmacy-Specialist Inj long-acting 250 mg - pre-filled syringe	45.00	3	✓ Primoteston
97	INFLUENZA VACCINE – Hospital pharmacy [Xpharm] Inj	75.00	10	✓ Vaxigrip
105	MORPHINE SULPHATE a) Only on a controlled drug form b) No patient co-payment payable Suppos 5 mg..... Suppos 10 mg	17.74 19.14	12 12	✓ RMS ✓ RMS
	Suppos 20 mg	20.31	12	✓ RMS
	Suppos 30 mg	31.39	12	✓ RMS
108	DIAZEPAM Inj 5 mg per ml, 2 ml – Subsidy by endorsement	16.64 (33.90)	10	Diazemuls
	a) Only on a PSO b) PSO must be endorsed “not for anaesthetic procedures”.			
144	LORATADINE * Tab 10 mg	8.50	30	✓ Loraclear Hayfever Relief
145	SALMETEROL – See prescribing guideline Aerosol inhaler, 25 µg per dose	26.46	120 dose OP	✓ Serevent
	Note: this product has been replaced by Serevent aerosol inhaler CFC-free			
146	SALBUTAMOL Nebuliser soln, 1 mg per ml, 2.5 ml – Available on a PSO	3.70 (4.83)	20	Ventolin Nebules
	Nebuliser soln, 2 mg per ml, 2.5 ml – Available on a PSO	3.85 (5.10)	20	Ventolin Nebules
177	AMINOACID FORMULA WITHOUT VALINE, LEUCINE AND ISOLEUCINE – Special Authority see SA0732 – Hospital pharmacy [HP3] See prescribing guideline Powder	487.38	500 g OP	✓ MSUD Aid III

Effective 1 September 2007

26	HYOSCINE N-BUTYLBROMIDE * Tab 10 mg	6.65 (10.85)	100	Buscopan
52	LISINAPRIL * Tab 5 mg	2.78 (4.91)	30	Prinivil
	* Tab 10 mg	3.16 (7.14)	30	Prinivil
	* Tab 20 mg	3.91 (10.10)	30	Prinivil

Patients pay a manufacturer's surcharge when
the Manufacturer's Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29
‡ safety cap reimbursed **Sole Subsidised Supply**

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

Delisted Items - effective 1 September 2007 (continued)

85	CEFTRIAZONE SODIUM – Hospital pharmacy [HP3] – Subsidy by endorsement a) Available on a PSO b) Subsidised only if prescribed for a dialysis or cystic fibrosis patient, or the treatment of confirmed ciprofloxacin-resistant gonorrhoea, or the treatment of suspected meningitis in patients who have a known allergy to penicillin, and the prescription or PSO is endorsed accordingly. Inj 250 mg	4.00	1	✓Rocephin IV
91	ACICLOVIR * Tab dispersible 200 mg	7.92 (10.00) 7.13 (48.75)	100 90	Acicvir Zovirax
	* Tab dispersible 400 mg	28.46 (36.00)	240	Acicvir
	* Tab dispersible 800 mg	21.09 (26.70)	100	Acicvir
91	VALACICLOVIR Tab 500 mg	1.58 (54.63) 4.74 (163.80)	10 30	Valtrex Valtrex
107	PAROXETINE HYDROCHLORIDE Tab 20 mg	5.90 (35.02)	30	Arpax
116	OLANZAPINE – Special Authority see SA0741– Retail pharmacy Tab 2.5 mg	54.72	30	✓Zyprexa
	Tab 5 mg	108.44	30	✓Zyprexa
	Tab 10 mg	219.10	30	✓Zyprexa
	Note – Zyprexa tab 2.5 mg, 5 mg and 10 mg 28 tablet pack size is still subsidised.			
117	TRIFLUOPERAZINE HYDROCHLORIDE Tab 5 mg	15.79 (17.77)	112	Stelazine Section 29 S29
125	CALCIUM FOLINATE Tab 15 mg – PCT – Hospital pharmacy [HP3]-Specialist.....	38.90 (55.60)	10	Leucovorin
152	BRIMONIDINE TARTRATE – Retail pharmacy-Specialist * Eye Drops 0.2%	8.95	5 ml OP	✓Alphagan
175	GLUTEN FREE BREAD MIX – Special Authority see SA0722 – Hospital pharmacy [HP3] Powder	4.77 (7.63)	1,000 g OP	Bakels Gluten Free Bread Mix

▲ Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

* Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

Items to be Delisted

Effective 1 October 2007

97	INFLUENZA VACCINE – Hospital pharmacy [Xpharm] Inj.....	75.00	10	✓ Vaxigrip
----	--	-------	----	------------

Effective 1 December 2007

64	CETOMACROGOL * Cream BP.....	2.80 (4.35)	500 g	IPW
66	MALATHION Liq 0.5%.....	4.99 (5.80)	200 ml	AFT
73	SODIUM CITRO-TARTRATE * Grans eff 4 g sachets	1.02 (2.40)	8	Ural

Note - the 28 pack size of Ural will continue to be available fully subsidised.

Effective 1 January 2008

29	METFORMIN HYDROCHLORIDE * Tab 500 mg	9.75	500	✓ Metomin
	* Tab 850 mg	8.00	250	✓ Metomin
47	DEXTROSE WITH ELECTROLYTES Soln with electrolytes	3.33 (3.44)	500 ml OP	Plasma-Lyte Oral
		6.30 (6.66)	946 ml OP	Pedialyte - Fruit
97	INFLUENZA VACCINE – Hospital pharmacy [Xpharm] Inj.....	7.50	1	✓ Fluvax

Effective 1 March 2008

28	INSULIN ISOPHANE WITH INSULIN NEUTRAL ▲ Inj human with neutral insulin 100 u per ml	25.26	10 ml OP	✓ Mixtard 50
	▲ Inj human with neutral insulin 100 u per ml, 3 ml	42.66	5	✓ PenMix 10 ✓ PenMix 20
55	ACEBUTOLOL * Tab 400 mg	27.63	100	✓ ACB
65	POVIDONE IODINE Oint 10%	2.88 6.87 (7.02)	25 g OP 100 g OP	✓ Biocil Betadine

a) Maximum of 100 g per prescription
b) Only on a prescription

continued...

Patients pay a manufacturer's surcharge when
the Manufacturer's Price is greater than the Subsidy

‡ safety cap reimbursed
S29 Unapproved medicine supplied under Section 29
Sole Subsidised Supply

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$

Per

Brand or
Generic Mnfr
✓ fully subsidised

Items to be delisted - effective 1 March 2008 (continued)

continued...

	Antiseptic soln 10%	6.42	500 ml	✓ Biocil
		64.20	5,000 ml	✓ Biocil
116	PIMOZIDE – Retail pharmacy-Specialist			
	Tab 4 mg	11.78	20	✓ Orap Forte \$29

Effective 1 April 2008

25	SULPHASALAZINE			
	Enema 3 g per 100 ml - Retail pharmacy - Specialist	37.40	7	Salazopyrin
		(43.00)		
46	DEXTROSE			
	* Inj 50%, 10 ml – Available on a PSO	8.25	5	✓ Mayne
87	BENZATHINE BENZYL PENICILLIN			
	Injection 1.2 mega u – Available on a PSO	160.00	10	✓ Pan Benzathine Benzylpenicillin
96	IBUPROFEN – Additional subsidy by Special Authority see SA0291 – Retail pharmacy			
	* Tab 600 mg	5.32	100	Brufen
		(22.80)		
99	TENOXCAM – Additional subsidy by Special Authority see SA0291 – Retail pharmacy			
	* Inj 10 mg per ml, 2 ml – Available on a PSO	10.00	5	✓ Tilcotil
113	DIMENHYDRINATE			
	* Tab 50 mg	0.59	10	Dramamine
		(3.07)		
117	THIORIDAZINE HYDROCHLORIDE			
	Tab 50 mg	10.66	90	✓ Aldazine
153	PILOCARPINE			
	* Eye drops 3%	6.41	15 ml OP	✓ Piloft
180	SOYA INFANT FORMULA – Special Authority see SA0604 – Retail pharmacy			
	Powder	6.34	900 g OP	Infasoy
		(18.32)		

▲ Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

* Three months or six months, as applicable, dispensed all-at-once

Contracted Pharmaceutical Description	Brand	Price (\$) (ex man. excl. GST)	Per	DV Limit	DV Limit applies from	DV Pharmaceutical
---------------------------------------	-------	--------------------------------	-----	----------	-----------------------	-------------------

Section H changes to Part II

Effective 1 October 2007

ALENDRONATE SODIUM WITH CHOLECALCIFEROL

Tab 70 mg with cholecalciferol
2,800 iu.....Fosamax Plus 35.91 4

CAPTOPRIL

Tab 12.5 mg.....**Apo-Captopril** 10.40 500 1% Dec-07 Capoten
Captohexal
Tab 25 mg.....**Apo-Captopril** 13.40 500 1% Dec-07 Capoten
Captohexal
Tab 50 mg.....**Apo-Captopril** 19.00 500 1% Dec-07 Capoten
Captohexal

CITALOPRAM HYDROBROMIDE

Tab 20 mg.....Citalopram - Rex 3.50 28

COLISTIN SULPHOMETHATE

Inj 150 mg.....**Colistin-Link** 65.00 1 1% Dec-07 (B)

FUSIDIC ACID († price)

Tab 250 mg.....Fucidin 43.67 12

HALOPERIDOL († price)

Inj 5 mg per ml, 1 mlSerenace 17.04 10

HYDROCORTISONE ACETATE

Rectal foam 10%, CFC-Free
(14 applications).....**Colifoam** 21.10 21.1 g 1% Dec-06 (B)

Note – change in presentation description

ISOFLURANE

Liq 250 ml bottle**Forthane** 99.00 250 ml 1% Jan-07 Aerrane
Abbott Forane Rhodia

Note – change in brand name only

LACTULOSE

Oral liq 10 g per 15 ml.....**Duphalac** 6.65 1000 ml 1% Dec-07 Actilax
Laevolac

LORATADINE

Tab 10 mg.....**Loraclear** 3.58 100 1% Dec-07 Apo-Loratadine
Hayfever Relief Aridine
Arrow-Loratadine
Claratyne
Lorastyne
Lora-tabs
Lorfast
Tirlor

MACROGOL 3350

Powder 13.125 g, sachets.....Movicol 18.14 30

Products with Hospital Supply Status (HSS) are in **bold**.

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Contracted Pharmaceutical Description	Brand	Price (\$) (ex man. excl. GST)	Per	DV Limit	DV Limit applies from	DV Pharmaceutical
---------------------------------------	-------	--------------------------------	-----	----------	-----------------------	-------------------

Section H changes to Part II - effective 1 October 2007 (continued)

MESALAZINE

Suppos 500 mg.....	Asacol	25.20	20			
Suppos 1 g.....	Pentasa	50.96	28			
Tab 400 mg.....	Asacol	49.50	100			

OMEPRAZOLE

Cap 10 mg.....	Dr Reddy's Omeprazole	2.99	28			
Cap 20 mg.....	Dr Reddy's Omeprazole	4.27	28			
Cap 40 mg.....	Dr Reddy's Omeprazole	5.01	28			

OXYBUTYNIN

Oral liq 5 mg per 5 ml.....	Apo-Oxybutynin	50.40	473 ml	1%	Dec-07	(B)
Tab 5 mg.....	Apo-Oxybutynin	44.79	500	1%	Dec-07	(B)

PACLITAXEL (↓ price)

Inj 30 mg.....	Taxol	90.00	1	1%	Sept-05	Anzatax Paclitaxel Ebewe
Inj 100 mg.....	Taxol	299.70	1	1%	Sept-05	Anzatax Paclitaxel Ebewe

PHENOXYMETHYLPENICILLIN (PENICILLIN V)

Grans for oral liq 125 mg per 5 ml.....	AFT	1.68	100 ml	1%	Dec-07	(B)
Grans for oral liq 250 mg per 5 ml.....	AFT	1.82	100 ml	1%	Dec-07	(B)

PODOPHYLLOTOXIN (↑ price)

Soln 0.5%.....	Condyline	38.00	3.5 ml			
----------------	-----------	-------	--------	--	--	--

POVIDONE IODINE

Alcohol skin preparation 10% with 30% alcohol.....	Betadine Skin Prep	8.13	500 ml			
Antiseptic soln 10%.....	Betadine	6.42	500 ml			
Oint 10%.....	Betadine	2.88	25 g			

QUETIAPINE (↓ price)

Tab 25 mg.....	Seroquel	46.20	60			
Tab 100 mg.....	Seroquel	92.40	60			
Tab 200 mg.....	Seroquel	158.76	60			
Tab 300 mg.....	Seroquel	267.12	60			

SIMVASTATIN

Tab 10 mg.....	SimvaRex	2.31	30			
Tab 20 mg.....	SimvaRex	2.81	30			
Tab 40 mg.....	SimvaRex	4.98	30			

Contracted Pharmaceutical Description	Brand	Price (\$) (ex man. excl. GST)	Per	DV Limit	DV Limit applies from	DV Pharmaceutical
---------------------------------------	-------	--------------------------------	-----	----------	-----------------------	-------------------

Section H changes to Part II - effective 1 October 2007 (continued)

SODIUM ACID PHOSPHATE

Enema 16% with sodium phosphate 8%	Fleet Phosphate Enema	2.50	1			
--	-----------------------	------	---	--	--	--

Effective 1 September 2007

AZITHROMYCIN

Tab 500 mg.....	Arrow-Azithromycin	9.90	2	1%	Nov-07	Zithromax
-----------------	---------------------------	------	---	----	--------	-----------

METHADONE HYDROCHLORIDE

Tab 5 mg.....	PSM	2.10	10	1%	Nov-07	Pallidone
---------------	------------	------	----	----	--------	-----------

OXYCODONE HYDROCHLORIDE

Inj 10 mg per ml, 1 ml	OxyNorm	14.40	5	1%	Nov-07	(B)
Inj 10 mg per ml, 2 ml	OxyNorm	28.80	5	1%	Nov-07	(B)
Oral liq 5 mg per 5 ml	OxyNorm	11.20	250 ml	1%	Nov-07	(B)

Effective 1 August 2007

EXEMESTANE

Tab 25 mg.....	Aromasin	175.00	30			
----------------	----------	--------	----	--	--	--

FLUOROURACIL SODIUM (↓ price and addition of HSS)

Inj 25 mg per ml 100 ml	Mayne	13.55	1	1%	Oct-07	(B)
Inj 50 mg per ml, 10 ml	Fluorouracil Ebewe	4.95	1	1%	Oct-07	Mayne
Inj 50 mg per ml, 20 ml	Fluorouracil Ebewe	8.60	1	1%	Oct-07	Mayne
Inj 50 mg per ml, 50 ml	Fluorouracil Ebewe	21.50	1	1%	Oct-07	Mayne
Inj 50 mg per ml, 100 ml	Fluorouracil Ebewe	43.00	1	1%	Oct-07	(B)

Note – Mayne’s brand of Fluorouracil sodium inj 50 mg per ml, 10 ml, 20 ml and 50 ml to be delisted 1 October 2007

GABAPENTIN (↓ price)

Cap 100 mg	Neurontin	15.67	100			
Cap 300 mg	Neurontin	47.00	100			
Cap 400 mg	Neurontin	62.66	100			
Tab 600 mg.....	Neurontin	79.79	100			

HYDROXOCOBALAMIN (Delisted effective 1 August 2007)

Inj 1 mg per ml, 1 ml	Neo-Cytamen	10.84	3			
-----------------------------	------------------------	------------------	--------------	--	--	--

IBUPROFEN

Oral liq 100 mg per 5 ml	Fenpaed	3.49	200 ml	1%	Oct-07	Nurofen
--------------------------------	----------------	------	--------	----	--------	---------

Contracted Pharmaceutical Description	Brand	Price (\$) (ex man. excl. GST)	Per	DV Limit	DV Limit applies from	DV Pharmaceutical
---------------------------------------	-------	--------------------------------	-----	----------	-----------------------	-------------------

Section H changes to Part II - effective 1 August 2007 (continued)

LOPINAVIR WITH RITONAVIR

Tab 200 mg with ritonavir 50 mgKaletra	735.00	120				
Oral liq 80 mg with ritonavir 20 mg per ml.....Kaletra	735.00	300 ml				

MESNA (addition of HSS)

Inj 100 mg per ml, 4 ml Uromitexan	109.63	15	1%	Oct-07	(B)
Inj 100 mg per ml, 10 ml Uromitexan	251.73	15	1%	Oct-07	(B)

OXYCODONE HYDROCHLORIDE

Tab controlled-release 5 mgOxyContin	7.51	20				
--	------	----	--	--	--	--

ZIPRASIDONE

Cap 20 mgZeldox	87.88	60				
Cap 40 mgZeldox	164.78	60				
Cap 60 mgZeldox	247.17	60				
Cap 80 mgZeldox	329.56	60				

Index

Pharmaceuticals and brands

A			
ACB	32	Condylone.....	35
Acebutolol.....	32	Cosopt.....	24
Aciclovir	23, 31	D	
Acicvir	31	Dexamethasone	23
Aldazine.....	33	Dexamethasone with framycetin and gramicidin	23
Alendronate sodium with cholecalciferol	34	Dexamethasone with neomycin and polymyxin b sulphate.....	23
Alphagan	31	Dextrose	33
Aminoacid formula without valine, leucine and isoleucine	30	Dextrose with electrolytes.....	27, 32
Apo-Captopril.....	27, 34	Diazemuls.....	30
Apo-Ipravent.....	21	Diazepam.....	30
Apo-Oxybutynin	28, 35	Diclofenac sodium	23
Apo-Timop.....	24	Digoxin	27
Aromasin.....	36	Dimenhydrinate.....	33
Aropax.....	31	Dorzolamide hydrochloride.....	24
Arrow-Azithromycin	21, 36	Dorzolamide hydrochloride with timolol maleate..	24
Asacol	27, 35	Dramamine	33
Azithromycin.....	21, 36	Dr Reddy's Omeprazole.....	20, 35
B		Duphalac	20, 34
Bakels Gluten Free Bread Mix	31	E	
Benzathine benzylpenicillin	33	Eltroxin	28
Betadine.....	27, 28, 32, 35	Exemestane	36
Betadine Skin Prep	35	F	
Betaferon	28	Fat.....	24
Betagan	23	Fenpaed.....	36
Betaloc CR.....	22, 27	Fleet Phosphate Enema	36
Betaxolol hydrochloride	23	Flucon.....	23
Betoptic	23	Fluorometholone	23
Betoptic S.....	23	Fluorouracil Ebewe.....	36
Biocil	32, 33	Fluorouracil sodium.....	36
Brimonidine tartrate.....	24, 31	Fluvax	32
Brimonidine tartrate with timolol maleate.....	24	Forthane	34
Brufen.....	20, 33	Fosamax Plus	34
Budesonide with eformoterol	20	Fucidin.....	28, 34
Buscopan	30	Fusidic acid.....	28, 34
C		G	
Calcium folinate	31	Gabapentin	36
Captopril.....	27, 34	Genoptic	23
Ceftriaxone sodium	31	Gentamicin sulphate.....	23
Cellcept	22	Gluten free bread mix	31
Cetomacrogol	32	H	
Ciloxan.....	23	Haloperidol	34
Ciprofloxacin.....	23	Hydrocortisone acetate	22, 34
Citalopram - Rex.....	20, 34	Hydrocortisone butyrate	29
Citalopram hydrobromide	20, 34	Hydroxocobalamin	36
Colestid	27	Hyoscine N-butylbromide	30
Colestipol hydrochloride.....	27	I	
Colifoam	22, 34	Ibuprofen	20, 33, 36
Colistin-Link.....	28, 34	Infasoy	33
Colistin sulphomethate	28, 34	Influenza vaccine.....	30, 32
Combigan	24	Insulin isophane with insulin neutral.....	32

Index

Pharmaceuticals and brands

Interferon beta-1-beta.....	28
Ipratropium bromide.....	21
Isosflurane.....	34
K	
Kaleta.....	37
L	
Lactulose.....	20, 34
Lanoxin.....	27
Lanoxin PG.....	27
Leucovorin.....	31
Levobunolol.....	23
Lisinopril.....	30
Lithium carbonate.....	29
Locoid.....	29
Lopinavir with ritonavir.....	37
Lopresor.....	27
Loraclear Hayfever Relief.....	21, 30, 34
Loratadine.....	21, 30, 34
M	
Macrogol 3350.....	20, 34
Malathion.....	29, 32
Maxidex.....	23
Maxitrol.....	23
Mesalazine.....	20, 27, 35
Mesna.....	37
Metformin hydrochloride.....	28, 32
Methadone hydrochloride.....	21, 36
Metomin.....	28, 32
Metoprolol succinate.....	22, 27
Metoprolol tartrate.....	27
Midazolam.....	20
Minims.....	24
Mixtard 50.....	32
Morphine sulphate.....	30
Movicol.....	20, 34
MSUD Aid III.....	30
Mycophenolate mofetil.....	22
N	
Neo-Cytamen.....	36
Neurontin.....	36
Nifuran.....	29
Nitrofurantoin.....	29
O	
Olanzapine.....	31
Omeprazole.....	20, 35
Ondansetron.....	26
Orap Forte.....	33
Oxybutynin.....	28, 35
Oxycodone hydrochloride.....	21, 29, 36, 37
OxyContin.....	37
OxyNorm.....	21, 29, 36
P	
Paclitaxel.....	28, 35
Paediatric products.....	25
Pan Benzathine Benzylpenicillin.....	33
Paroxetine hydrochloride.....	31
Pedialyte - Fruit.....	27, 32
PenMix 10.....	32
PenMix 20.....	32
Pentasa.....	20, 35
Phenoxymethylpenicillin (Penicillin V).....	22, 28, 35
Phenylephrine hydrochloride.....	29
Pilocarpine.....	24, 33
Pilopt.....	33
Pimozide.....	33
Plasma-Lyte Oral.....	27, 32
Podophyllotoxin.....	35
Povidone iodine.....	27, 28, 32, 35
Pred Forte.....	24
Pred Mild.....	24
Prednisolone acetate.....	24
Prefrin.....	29
Priadel.....	29
Primoteston.....	30
Prinivil.....	30
Q	
Quetiapine.....	22, 28, 35
R	
Rocephin IV.....	31
S	
S26 Soy.....	21
Salazopyrin.....	33
Salbutamol.....	30
Salmeterol.....	30
Serenace.....	34
Serevent.....	30
Seroquel.....	22, 28, 35
SimvaRex.....	20, 35
Simvastatin.....	20, 35
Sodium acid phosphate.....	36
Sodium citro-tartrate.....	32
Sofradex.....	23
Soya infant formula.....	21, 33
Stelazine Section 29.....	31
Sulphasalazine.....	33
Symbicort Rapihaler.....	20
T	
Taxol.....	28, 35
Tenoxicam.....	33
Testosterone enanthate.....	30
Thioridazine hydrochloride.....	33
Thyroxine.....	28
Tilcotil.....	33

Index

Pharmaceuticals and brands

Timolol maleate.....	24	Vaxigrip	30, 32
Timoptol XE	24	Ventolin Nebules	30
Tobramycin.....	24	Voltaren Ophtha	23
Tobrex	24	W	
Trifluoperazine hydrochloride.....	31	Water.....	29
Trusopt.....	24	Z	
U		Zeldox.....	37
Ural.....	32	Ziprasidone	37
Uromitexan	37	Zofran	26
V		Zofran Zydis	26
Valaciclovir	31	Zovirax.....	23, 31
Valtrex	31	Zyprexa.....	31



While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the Update.

Pharmaceutical Management Agency
Level 14 Cigna House, 40 Mercer Street
PO Box 10 254 Wellington, New Zealand
Telephone 64 4 460 4990 Facsimile 64 4 460 4995
Freephone information line (9am - 4pm weekdays) 0800 66 00 50
www.pharmac.govt.nz